Schnizler syndrome


Cite item

Full Text

Abstract

Urticarial skin lesions can be the first manifestation of various systemic disorders. Schnizler syndrome (SS) is a rare systemic disease that includes chronic urticaria, monoclonal IgM-gammapathy, bone pain and other clinical presentations. In this report, we present two patients with diagnosed SS. This is the first recorded observation of the syndrome in Russia. The patients are males of the same age group (47- and 50 years old). The clinical diagnosis of SS was confirmed by histological and laboratory studies. It is of interest, that one patient had a good response to the treatment with pefloxacin and rituximab while the other experienced improvement on elimination diet. In addition, we observed hyperimmunoglobulinaemia E in one of patients with SS, the phenomenon that has not been described in world literature so far.

About the authors

P. V Kolkhir

Research Department of Immunodependent Dermatoses, Research Center

Email: arthate@yandex.ru
врач-аллерголог, кандидат мед. наук, старший научный сотрудник

E. A Muravyova

Clinic of Nephrology, Visceral and Occupational Diseases

Department of Skin and Sexually-Transmitted Diseases, Therapeutic Faculty

O. Yu Olisova

Clinic of Nephrology, Visceral and Occupational Diseases

Department of Skin and Sexually-Transmitted Diseases, Therapeutic Faculty

E. A Nikitin

ФБГУ Гематологический научный центр Минздрава России

кандидат мед. наук

P. I Novikov

Clinic of Nephrology, Visceral and Occupational Diseases

врач, заведующий ревматологическим отделением; ревматологическое отделение

V. S Moiseev

ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России

Department of Visceral, Occupational Diseases, and Pulmonology

L. R Plieva

I.M. Setchenov First Moscow State Medical University

кандидат мед. наук, врач, заведующая вторым кожно-венерологическим отделением; клиника кожных и венерических болезней им. В.А. Рахманова

T. P Nekrasova

Hematology Research Center

кандидат медицинских наук, доцент; кафедра патологической анатомии им. академика А.И. Струкова

D. S Pogorelov

ГБОУ ВПО Ростовский государственный медицинский университет Минздрава России

врач-ординатор; кафедра кожных и венерических болезней

References

  1. Simon A., Asli B., Braun-Falco M., De Koning H., Feimand J.-P., Grattan C., et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy. 2013; 68(5): 562-8. doi: 10.1111/all.12129.
  2. Schnitzler L. Lesions urticariennes chroniques permanentes (erytheme petaloide?). Cas cliniques. J. Dermatol. Angers. 1972: abstr. 46.
  3. Lipsker D., Veran Y, Grunenberger F., Cribier B., Heid E., Gross-hans E. The Schnitzler syndrome: Four new cases and review of the literature. Medicine (Baltimore). 2001; 80(1): 37-44.
  4. Besada E., Nossent H. Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler’s syndrome: a case report and literature review. Clin. Rheumatol. 2010; 29(5): 567-71.
  5. Schuster C., Kranke B., Aberer E., Arbab E., Sturm G., Aberer W. Schnitzler syndrome: response to anakinra in two cases and a review of the literature. Int. J. Dermatol. 2009; 48(11): 1190-4.
  6. Volz T., Wolbing F., Fischer J., Braun M., Maggoschitz I., Schaller M., et al. Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin-1 receptor antagonist anakinra in Schnitzler syndrome. Acta Dermatol. Venereol. 2012; 92(4): 393-4. doi: 10.2340/00015555-1307.
  7. Carbone J., Paravisini A., Sarmiento E., Rodriguez-Molina J., Fernandez-Cruz E. Partial response to cyclosporine in a patient with Schnitzler’s syndrome. Allergol. Immunopathol. (Madr). 2007; 35(2): 71-3.
  8. Asli B., Bienvenu B., Cordoliani F., Brouet J.C., Uzunhan Y, Arnulf B., et al. Chronic urticaria and monoclonal IgM gammop-athy (Schnitzler syndrome): report of 11 cases treated with pefloxacin. Arch. Dermatol. 2007; 143(8): 1046-50.
  9. Murota H., Shoda Y., Ishibashi T., Sugahara H., Matsumura I., Katayama I. Improvement of recurrent urticaria in a patient with Schnitzler syndrome associated with B-cell lymphoma with combination rituximab and radiotherapy. J. Am. Acad. Dermatol. 2009; 61 (6): 1070-5. doi: 10.1016/j.jaad.2008.12.040.
  10. Cascavilla N., Bisceglia M., D’Arena G. Successful treatment of Schnitzler’s syndrome with anakinra after failure of rituximab trial. Int. J. Immunopathol. Pharmacol. 2010; 23(2): 633-6.
  11. Eiling E., Moller M., Kreiselmaier I., Brasch J., Schwarz T. Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J. Am. Acad. Dermatol. 2007; 57(2): 361-4.
  12. Kyle R.A., Therneau T.M., Rajkumar S.V, Remstein E.D., Offord J.R., Larson D.R., et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003; 102(10): 3759-64.
  13. Launay D., Dutoit-Lefevre V, Faure E., Robineau O., Hauspie C., Sobanski V., et al. Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome. PLoS One. 2013; 8(3): e59327. doi: 10.1371/journal.pone.0059327.
  14. Kluger N., Bessis D., Guillot B. Tocilizumab as a potential treatment in Schnitzler syndrome. Med. Hypotheses. 2009; 72(4): 479-80. doi: 10.1016/j.mehy.2008.12.002.
  15. Ramadan K.M., Eswedi H.A., El-Agnaf M.R. Schnitzler syndrome: a case report of successful treatment using the anti-CD20 monoclonal antibody rituximab. Br. J. Dermatol. 2007; 156(5): 1072-4.
  16. Killock D. Lupus nephritis: A rituximab-based regimen might enable oral steroid avoidance in lupus nephritis. Nat. Rev. Rheumatol. 2013; 9(8): 443. doi: 10.1038/nrrheum.2013.102.
  17. Alten R., Maleitzke T. Tocilizumab: a novel humanized antiinterleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Ann. Med. 2013; 45(4): 357-63. doi: 10.3109/07853890.2013.771986.
  18. Tinazzi E., Puccetti A., Patuzzo G., Sorleto M., Barbieri A., Lunardi C. Schnitzler syndrome, an autoimmune-autoinflammatory syndrome: Report of two new cases and review of the literature. Auto-immun. Rev. 2011; 10(7): 404-9. doi: 10.1016/j.autrev.2011.01.003.
  19. Lipsker D., Spehner D., Drillien R., Schmitt P., Cribier B., Heid E., et al. Schnitzler syndrome: heterogeneous immuno-pathological findings involving IgM-skin interactions. Br. J. Dermatol. 2000; 142(5): 954-9.
  20. Asli B., Bienvenu B., Cordoliani F., Brouet J.C., Uzunhan Y., Arnulf B., et al. Chronic urticaria and monoclonal IgM gammopathy (Schnitzler syndrome): report of 11 cases treated with pefloxacin. Arch. Dermatol. 2007; 143(8): 1046-50.
  21. Dalhoff A., Shalit I. Immunomodulatory effects of quinolones. Lancet Infect. Dis. 2003; 3(6): 359-71.
  22. Sperr W.R., Natter S., Baghestanian M., Smolen J., Wolff K., Binder B.R., et al. Autoantibody reactivity in a case of Schnitler’s syndrome: evidence for a Th1-like response and detection of IgG2 antiFcsRIa antibodies. Int. Arch. Allergy Immunol. 2000; 122(2): 279-86.
  23. Saurat J.H., Schifferli J., Steiger G., Dayer J.M., Didierjean L. Anti-interleukin-1 alpha autoantibodies in humans: characterization, isotype distribution and receptorbinding inhibition-higher frequency in Schnitzler’s syndrome (urticaria and macroglobu-linemia). J. Allergy Clin. Immunol. 1991; 88(2): 244-56.
  24. Rybojad M., Moraillon I., Cordoliani F., Lebbe C., Baccard M., Fla-geul B., et al. Schnitzler syndrome and genetic deficiency of C4. Two cases report. Ann. Dermatol. Venereol. 1993; 120(11): 783-5.
  25. Govindaraju S., Brochot P., Ringot A.C., Paternotte L., Morrone A., Eschard J.P., Etienne J.C. Chronic urticaria-macroglobulin-emia (Schnitzler syndrome): developing to IgM myeloma. Apropos of a case. Rev. Med. Interne. 1993; 14(8): 780-3.
  26. Worm M., Kolde G. Schnitzler’s syndrome: successful treatment of two patients using thalidomide. Br. J. Dermatol. 2003; 148(3): 601-2.
  27. Lecompte M., Blais G., Bisson G., Maynard B. Schnitzler’s syndrome. Skeletal. Radiol. 1998; 27(5): 294-6.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies